Blueprint
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2017.
Commission File Number: 000-53805
Intellipharmaceutics International Inc.
(Translation of registrant's name into English)
30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ x
] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1):
Note: Regulation S-T Rule
101(b)(1) only permits the submission in paper of a Form 6-K if
submitted solely to provide an attached annual report to security
holders.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7):
Note: Regulation S-T Rule
101(b)(7) only permits the submission in paper of a Form 6-K if
submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws
of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant’s “home
country”), or under the rules of the home country exchange on
which the registrant’s securities are traded, as long as the
report or other document is not a press release, is not required to
be and has not been distributed to the registrant’s security
holders, and, if discussing a material event, has already been the
subject of a Form 6-K submission or other Commission filing on
EDGAR.
This Report of Foreign Private Issuer on Form 6-K and the attached
exhibits 99.1, 99.2 and 101 shall be incorporated by reference into
the Company’s effective Registration Statements on Form F-3,
as amended and supplemented (Registration Statement Nos. 333-172796
and 333-196112), filed with the Securities and Exchange Commission,
from the date on which this Report is filed, to the extent not
superseded by documents or reports subsequently filed or furnished
by Intellipharmaceutics International Inc. under the Securities Act
of 1933 or the Securities Exchange Act of 1934.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly
authorized.
|
|
|
Intellipharmaceutics
International Inc.
(Registrant)
/s/
Domenic Della Penna
|
|
Date: April 11, 2017
|
|
Domenic Della Penna
Chief Financial Officer
|
EXHIBIT LIST
|
Exhibit
|
Description
|
|
99.1
|
Management Discussion And Analysis Of Financial Condition And
Results Of Operations for the Three Months Ended February 28,
2017
|
|
99.2
|
Condensed Unaudited Interim Consolidated Financial Statements and
Notes to Condensed Unaudited Interim Consolidated Financial
Statements of Intellipharmaceutics International Inc. for the Three
Months Ended February 28, 2017
|
|
99.3
|
News Release dated April 11, 2017 - Intellipharmaceutics Announces
First Quarter 2017 Results
|
|
99.4
|
Form 52-109F2 - Chief Executive Officer
|
|
99.5
|
Form 52-109F2 - Chief Financial Officer
|
|
101
|
XBRL (Extensible Business Reporting Language). The following
materials from Intellipharmaceutics International Inc.’s
Condensed Unaudited Interim Consolidated Financial Statements and
Notes to the Condensed Unaudited Interim Consolidated Financial
Statements for the three months ended February 28, 2017, formatted
in XBRL:
|
|
|
(i)
Condensed unaudited interim
consolidated balance sheets as at February 28, 2017 and November
30, 2016
(ii)
Condensed unaudited interim
consolidated statements of operations and comprehensive loss for
the three
months
ended February 28, 2017 and February 29, 2016
(iii)
Condensed unaudited interim
consolidated statements of shareholders’ equity (deficiency)
for the three
months
ended February 28, 2017 and February 29, 2016
(iv)
Condensed unaudited interim
consolidated statements of cash flows for the three months ended
February
28,
2017 and February 29, 2016
(v)
Notes to the Condensed unaudited
interim consolidated financial statements
|